People: Avanir Pharmaceuticals Inc (AVNR.OQ)
AVNR.OQ on NASDAQ Stock Exchange Global Select Market
4.83USD
1:35pm EDT
4.83USD
1:35pm EDT
Price Change (% chg)
$0.07 (+1.47%)
$0.07 (+1.47%)
Prev Close
$4.76
$4.76
Open
$4.74
$4.74
Day's High
$4.93
$4.93
Day's Low
$4.72
$4.72
Volume
386,545
386,545
Avg. Vol
447,082
447,082
52-wk High
$5.09
$5.09
52-wk Low
$2.07
$2.07
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Craig Wheeler |
52 | 2007 | Independent Chairman of the Board |
Keith Katkin |
41 | 2007 | President, Chief Executive Officer, Director |
Christine Ocampo |
40 | 2010 | Principal Financial Officer, Vice President - Finance |
Joao Siffert |
48 | 2011 | Senior Vice President - Research and Development, Chief Scientific Officer |
Gregory Flesher |
42 | 2011 | Senior Vice President - Corporate Development, Chief Business Officer |
Randall Kaye |
50 | 2007 | Senior Vice President - Medical Affairs, Chief Medical Officer |
Rohan Palekar |
47 | 2012 | Senior Vice President, Chief Commercial Officer |
Corinne Nevinny |
53 | 2013 | Director |
Hans Bishop |
48 | 2012 | Independent Director |
David Mazzo |
56 | 2005 | Independent Director |
Dennis Podlesak |
55 | 2005 | Independent Director |
Scott Whitcup |
53 | 2005 | Independent Director |
Ian Clements |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Craig Wheeler |
Mr. Craig A. Wheeler is Independent Chairman of the Board of Avanir Pharmaceuticals Inc. Mr. Wheeler serves as a director and as Chief Executive Officer of Momenta Pharmaceuticals, Inc. Prior to joining Momenta in August 2006, Mr. Wheeler was President of Chiron BioPharmaceuticals for five years, a division of Chiron Corporation, until it was acquired by Novartis AG in 2006. In this position he was responsible for all aspects of the division including commercial, research, development and manufacturing. Mr. Wheeler serves on the board of directors for the Generic Pharmaceutical Associates (GPHA) and is a member of their executive committee. He currently serves on the Cornell Biomedical Engineering Advisory Board, and serves on the Gene Partnership Advisory Board for the Children’s Hospital of Boston. Mr. Wheeler holds B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania, where he in marketing and finance. |
Keith Katkin |
Mr. Keith A. Katkin is President, Chief Executive Officer, Director of Avanir Pharmaceuticals Inc. From July 2005 until March 2007, Mr. Katkin served as Senior Vice President of Sales and Marketing. Prior to joining Avanir, Mr. Katkin previously served as Vice President, Commercial Development for Peninsula Pharmaceuticals, playing a key role in the management and ultimate sale of the company to Johnson & Johnson in 2005. Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Amgen and Abbott Laboratories. Mr. Katkin also served as strategic advisor to Cerexa, a pharmaceutical company that was sold to Forest Laboratories in 2007. Mr. Katkin received a B.S. degree in Business and Accounting from Indiana University and an M.B.A. degree in Finance from the Anderson School of Management at UCLA, graduating with honors. Mr. Katkin became a licensed Certified Public Accountant in 1995. |
Christine Ocampo |
Ms. Christine G. Ocampo, CPA, is Principal Financial Officer, Vice President - Finance of Avanir Pharmaceuticals Inc. Prior to joining the Company, Ms. Ocampo served as Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer and Secretary of Cardiogenesis Corporation, a medical device company, from November 2003 until April 2006. From 2001 to November 2003, Ms. Ocampo served in the role of Vice President and Corporate Controller at Cardiogenesis. Prior to joining Cardiogenesis in April 1997, Ms. Ocampo held a management position in Finance at Mills-Peninsula Health Systems in Burlingame, California, and spent three years as an auditor for Ernst & Young LLP. Ms. Ocampo graduated with a Bachelor of Science in Accounting from Seattle University and became a licensed Certified Public Accountant in 1996. |
Joao Siffert |
Dr. Joao Siffert, M.D., is Senior Vice President - Research and Development, Chief Scientific Officer of Avanir Pharmaceuticals, Inc. Dr. Siffert previously served as Vice President and Chief Medical Officer at Ceregene, Inc., a biotechnology company focused on the development of neurotrophic gene therapies for Alzheimer’s and Parkinson’s diseases, from September 2007 to August 2011. Prior to his work at Ceregene, Dr. Siffert served as the Chief Medical Officer at Avera Pharmaceuticals, a CNS specialty pharmaceutical company, from May 2005 to September 2007. Prior to joining Avera, Dr. Siffert held positions with Pfizer (from February 2002 to May 2005) first as a medical director for Relpax and subsequently as the worldwide medical team leader of Lyrica and Neurontin focusing in areas of pain and epilepsy. Prior to Pfizer, Dr. Siffert held academic positions at Beth Israel Medical Center, where he served as director of the Adult Neuro-Oncology program, and Albert Einstein College of Medicine, where he was assistant professor of neurology. Dr. Siffert completed residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School. Dr. Siffert was certified by the American Board of Neurology and Psychiatry in 1996. He holds an M.D. degree from the University of Sao Paulo School of Medicine as well as an M.B.A. degree from Columbia University Business School. |
Gregory Flesher |
Mr. Gregory J. Flesher is Senior Vice President - Corporate Development, Chief Business Officer of Avanir Pharmaceuticals Inc. From August 2007 to February 2011, he served as Vice President of Business Development. From June 2006 to August 2007, he served as Senior Director of Commercial Strategy and, in November 2006, assumed the additional responsibility for Business Development and Portfolio Planning. Prior to joining Avanir, Mr. Flesher held positions as Director of Sales — Hepatology (from 2004 to 2006) and Director of Marketing — Pulmonary at InterMune, Inc. (from 2002 to 2004). Prior to his tenure at InterMune, Mr. Flesher held both oncology and nephrology marketing positions with Amgen Inc., a global biotechnology company, from 1999 to 2002. Mr. Flesher also has global marketing and clinical development experience from Eli Lilly and Company, where he worked from 1995 to 1998. Mr. Flesher graduated from Purdue University with a Bachelor of Science in Biology. |
Randall Kaye |
Dr. Randall E. Kaye, M.D., is Senior Vice President - Medical Affairs, Chief Medical Officer of Avanir Pharmaceuticals Inc. From November 2006 until March 2007, he served as Vice President Clinical and Medical Affairs, and from January 2006 to November 2006 as Vice President of Medical Affairs. Immediately prior to joining Avanir, Dr. Kaye was the Vice President of Medical Affairs for Scios Inc., a division of Johnson & Johnson, from 2004 to 2006. From 2002 to 2004, Dr. Kaye recruited and managed the Medical Affairs department for InterMune Inc. Previously, Dr. Kaye served for nearly a decade in Medical Affairs and Marketing positions for Pfizer Inc. Dr. Kaye earned his Doctor of Medicine, Masters in Public Health and Bachelor of Science degrees at George Washington University in Washington, D.C. and was a Research Fellow in Allergy and Immunology at Harvard Medical School. |
Rohan Palekar |
Mr. Rohan Palekar is Senior Vice President, Chief Commercial Officer of Avanir Pharmaceuticals, Inc. Mr. Palekar has over 20 years of experience in the biopharmaceutical industry and has worked on brands including Remicade® and Stelara®, as well as the investigational therapy MDV3100. Mr. Palekar’s most recent commercial leadership role was as Chief Commercial Officer for Medivation Inc., a biopharmaceutical company, from January 2008 to September 2011, where he was responsible for all commercial activities, chemistry, manufacturing and controls & manufacturing and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, from July 1991 to January 2008, in various senior commercial and strategic management roles, most recently as a Vice President of Sales & Marketing at Centocor, Inc., a subsidiary of Johnson & Johnson, where he launched two new indications for Remicade. Prior to that, Mr. Palekar was the worldwide Vice President of Immunology and held marketing leadership roles at McNeil Consumer and Specialty Pharmaceuticals. Mr. Palekar earned his M.B.A. degree from the Amos Tuck School of Business Administration Dartmouth College, his B.Com. in Accounting from the University of Bombay and his L.L.B. in Law from the University of Bombay. |
Corinne Nevinny |
Ms. Corinne H. Nevinny has been appointed as Director of Avanir Pharmaceuticals, Inc. Ms. Nevinny is General Partner of LMNVC LLC, a privately held early stage venture firm, which she founded in October 2010. Prior to that position, Ms. Nevinny served as corporate vice president for seven years at Edwards Lifesciences Corporation, a cardiovascular technology company. She held several positions at the company including general manager of Cardiac Surgery Systems and Vascular, president of Global Operations, and chief financial officer and treasurer. Other positions Ms. Nevinny held included vice president and chief financial officer of Tularik, Inc, a biotechnology company acquired by Amgen and executive director in the health care group at Warburg Dillon Read LLC, an investment bank. Ms. Nevinny also serves on the board of directors of Onyx Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., as well as three private companies. Ms. Nevinny received her undergraduate degree from Stanford University and her M.B.A. from Harvard Business School. |
Hans Bishop |
Mr. Hans Edgar Bishop is Independent Director of Avanir Pharmaceuticals, Inc. Mr. Bishop is the chief operating officer of Photothera Inc., a late stage medical device company. Prior to joining Photothera Inc., Mr. Bishop served as Executive Vice President and Chief Operating Officer at Dendreon Corporation from January 2010 to September 2011. His previous roles have included President of the specialty medicine business at Bayer Healthcare Pharmaceuticals Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology and hematology products, growing the division into a €3 billion global franchise. Mr. Bishop also held various positions at Chiron Corporation, Glaxo Wellcome, and SmithKline Beecham. In addition, he served as Executive Vice President of operations with a global telecom service company. Mr. Bishop currently serves as a member of the board of Photothera Inc. and chairman of the board of Genesis Biopharma, Inc., a biotechnology company. Mr. Bishop received a B.S. degree in chemistry from Brunel University in London. |
David Mazzo |
Dr. David J. Mazzo, Ph.D., is Independent Director of Avanir Pharmaceuticals Inc. Currently, he is the President and Chief Executive Officer and member of the board of Regado Biosciences, Inc., a privately held, U.S.-based biopharmaceutical company developing novel aptamer-reversal agent pairs initially in the area of injectable antithrombotics. From April 2007 through March 2008, Dr. Mazzo served as President and Chief Executive Officer and member of the board of Æterna Zentaris, Inc., a global biopharmaceutical company with products and a therapeutic focus in the areas of oncology and endocrinology. From April 2003 through March 2007, Dr. Mazzo served as President and Chief Executive Officer and member of the board of Chugai Pharma USA, a pharmaceutical company. Dr. Mazzo has spent more than 28 years in the pharmaceutical industry and has held positions of increasing responsibility with Merck, Baxter, Rhône-Poulenc Rorer, Hoechst Marion Roussel and Schering-Plough. Dr. Mazzo holds a B.A. degree in Honors (Interdisciplinary Humanities) and a B.S. degree in Chemistry from Villanova University, as well as an M.S. degree in Chemistry and a Ph.D. degree in Analytical Chemistry from the University of Massachusetts (Amherst). He further complemented his American education as a Research Fellow at the Ecole Polytechnique Fédérale de Lausanne, Switzerland. Dr. Mazzo serves as non-executive Chairman of the board of directors of pSivida, Inc., a global public biopharmaceutical company. |
Dennis Podlesak |
Mr. Dennis G. Podlesak is Independent Director of Avanir Pharmaceuticals Inc. Since November 2007, Mr. Podlesak has been a Partner with Domain Associates LLC, a life science focused venture capital firm, and has over 20 years of experience within the pharmaceutical industry. Prior to Domain, from 2005 to 2007, Mr. Podlesak served as the Chief Executive Officer and a member of the board of directors of Cerexa, Inc., a biotechnology company. Cerexa, Inc. became a wholly owned subsidiary of Forest Laboratories after being acquired by Forest in January 2007. Mr. Podlesak has served on a number of public company and private boards, and is currently a member of the board of directors of Adynxx, a pharmaceutical company, Regado Biosciences, a biotechnology company and Syndax Pharmaceuticals, a pharmaceutical company and the non-profit organization Prevent Blindness. Additionally, Mr. Podlesak was Executive Chairman of Corthera, Inc., a biopharmaceutical company, which was acquired by Novartis AG in January 2010 and was also a Founder, Chief Executive Officer, and board member of Calixa Therapeutics, Inc., a biopharmaceutical company, which was acquired by Cubist Pharmaceuticals, Inc. in December 2009. Mr. Podlesak received a B.A. degree and an M.B.A. degree from Pepperdine University and has completed postgraduate studies at the Wharton School, University of Pennsylvania. |
Scott Whitcup |
Dr. Scott M. Whitcup, M.D., is Independent Director of Avanir Pharmaceuticals Inc. He serves as Executive Vice President and Head of Research and Development of Allergan, Inc. Dr. Whitcup has served in this role since July 2004 and is responsible for Allergan’s drug discovery efforts, as well as the ophthalmology, Botox®/neurology, urology, skin care, medical devices and other new technology development programs worldwide. Dr. Whitcup was given the additional title of Chief Scientific Officer in 2009. Dr. Whitcup joined Allergan in January 2000 as Vice President, Development, Ophthalmology and, in January 2004, he became Allergan’s Senior Vice President, Development, Ophthalmology. From 1993 until 2000, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute / David Geffen School of Medicine at UCLA. Dr. Whitcup graduated from Cornell University Medical College and completed residency training both in internal medicine at UCLA Medical Center and in ophthalmology at the Massachusetts Eye and Ear Infirmary-Harvard Medical School. He then received fellowship training in uveitis and ocular immunology at the National Eye Institute. Dr. Whitcup is currently a member of the board of Questcor Pharmaceuticals, Inc., a pharmaceutical company. |
Ian Clements |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Craig Wheeler |
-- |
Keith Katkin |
1,582,950 |
Christine Ocampo |
500,715 |
Joao Siffert |
657,610 |
Gregory Flesher |
-- |
Randall Kaye |
856,817 |
Rohan Palekar |
1,258,270 |
Corinne Nevinny |
-- |
Hans Bishop |
-- |
David Mazzo |
-- |
Dennis Podlesak |
-- |
Scott Whitcup |
-- |
Ian Clements |
-- |
As Of 29 Sep 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Craig Wheeler |
0 | 0 |
Keith Katkin |
408,150 | 938,927 |
Christine Ocampo |
157,250 | 352,053 |
Joao Siffert |
0 | 0 |
Gregory Flesher |
0 | 0 |
Randall Kaye |
255,472 | 650,751 |
Rohan Palekar |
0 | 0 |
Corinne Nevinny |
0 | 0 |
Hans Bishop |
0 | 0 |
David Mazzo |
0 | 0 |
Dennis Podlesak |
0 | 0 |
Scott Whitcup |
0 | 0 |
Ian Clements |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
OCAMPO CHRISTINE G |
38,700 | $0.88 |
KATKIN KEITH A |
159,638 | $0.88 |
KATKIN KEITH A |
35,000 | $3.26 |
OCAMPO CHRISTINE G |
15,000 | $0.88 |
OCAMPO CHRISTINE G |
57,700 | $3.28 |
KATKIN KEITH A |
215,438 | $3.26 |
OCAMPO CHRISTINE G |
4,000 | $0.88 |
OCAMPO CHRISTINE G |
20,000 | $3.29 |
KATKIN KEITH A |
55,800 | $0.53 |
NEVINNY CORINNE HELENE |
58,350 | $0.00 |
MAZZO DAVID J |
38,900 | $0.00 |
BISHOP HANS EDGAR |
19,450 | $0.00 |
WHEELER CRAIG A |
38,900 | $0.00 |
PODLESAK DENNIS G |
38,900 | $0.00 |
WHITCUP SCOTT M |
38,900 | $0.00 |
KATKIN KEITH A |
73,125 | $0.00 |
SIFFERT JOAO |
49,125 | $0.00 |
OCAMPO CHRISTINE G |
8,963 | $0.00 |
SIFFERT JOAO |
34,875 | $0.00 |
PALEKAR ROHAN |
26,156 | $0.00 |
OCAMPO CHRISTINE G |
21,288 | $0.00 |
KATKIN KEITH A |
147,375 | $0.00 |
PALEKAR ROHAN |
36,844 | $0.00 |
PALEKAR ROHAN |
10,000 | $2.46 |
KATKIN KEITH A |
18,250 | $2.55 |

